There are numerous companies and products in the market for quantitative analysis of in vitro diagnostics. What is the difference between in vitro diagnostic quantitative analysis of LINZHI Technology? Then their way is really a unique way. Traditional in vitro diagnostic quantitative analysis methods are inseparable from the front-end detection hardware. Whether it is blood or urine analysis, the front-end hardware needs to collect samples, and then the sample data is analyzed to diagnose certain biochemical indicators.
“The detection results of hardware inevitably have errors. Hardware as an industrial product, the production process is more or less flawed, it also means that even if the user detects all the external interference during the detection process, POCT self-test is accurate and effective. It is also difficult to avoid the error caused by the hardware itself.” LINZHI Technology founder Huang Jiezhen evaluated the traditional in vitro diagnosis. “I have been involved in POCT-related software and hardware development. I have seen problems with hardware-based in vitro testing. Try to be a software service provider for POCT, reduce the cost of people’s testing, and increase detection scenarios and detections.”
POCT is a kind of instant test, which can also be called “bedside detection”. As the name implies, it is a new type of detection method that allows doctors to quickly detect by portable analytical instruments at the patient’s bedside (sampling site). This type of detection is not limited by the time and location of the diagnosis, and the patient can complete the diagnosis in minutes or even seconds.
Based on the many advantages of POCT, Huang Jiezhen judges that instant detection can become the preferred in vitro detection method for getting rid of hardware in the future. Huang Jiewei is a professional background in communication engineering. He has been engaged in the design and development of POCT quantitative products. However, for a professional company in the field of medical testing, it seems that the real application of POCT software to medical scenes is a cross-border.
Huang Jiexi explained: “Although the technical barriers in the medical field are high, LINZHI Technology is an application extension based on the existing technology, which avoids the problem of high barriers to a certain extent.” POCT technology already exists in the market. Image recognition technology has also been widely used in the market. LINZHI Technology is on the shoulder of these technologies, enabling application integration to empower and optimize existing technologies.
What kind of application fusion is this? How to achieve in vitro testing of pure software? This is probably the most confusing place. Huang Jiezhen explained to the arterial network reporter: “We only need a test strip and a mobile phone to achieve in vitro testing. The user first collects urine, blood or saliva through the test paper, and then uses the mobile phone to take pictures and send the image information of the test paper. To our system. According to the change of image recognition test paper, the system can intelligently analyze the physiological results of the patient according to the established model, and then combine the matching dictionary to transmit the test data and prevention, treatment plan and opinions to the patient for reference. And choice.”
When LINZHI Technology attempts to achieve in vitro diagnosis through digital quantitative analysis, it will take into account the external disturbances such as the interference of the background light source during imaging and the sensitivity of the POCT test paper itself into the development of the algorithm, and ensure the accuracy of the results from the data level. . The software will also guide the user to use under the most suitable environmental conditions when the user uses it, similar to the structured guidance when uploading the ID card, and try to ensure the accuracy of the front-end data collection.
In addition to the image to obtain the front-end data, LINZHI Technology will try other forms, such as video, slice, etc. to expand the front-end data acquisition, to further ensure the realism of the front-end data acquisition.
At present, LINZHI Technology’s POCT algorithm can detect more than 200 kinds of physiological parameters, including hormones, tumor markers, myocardial, infectious inflammation, diabetic nephropathy markers, infectious diseases, drug abuse, food safety. Subdivided detection items. The detection method involves quantitative analysis of a solid phase reagent such as a dry method, a colloidal gold method, a latex method, and a liquid phase reagent such as a colorimetric method, a ph indicator method, or an immunoturbidimetric method.
Among them, LINZHI Technology’s detection of human chorionic gonadotropin and luteinizing hormone has been basically perfected, which can be used for the diagnosis of reproductive fertility, and accurately determine the pregnant days and ovulation time of pregnant women.
Huang Jiewei stressed: “Modern people are paying more and more attention to their own health, but many people do not pay enough attention when the disease is only a small symptom, do not do related tests, when the small symptoms deteriorate into a large disease, the treatment is difficult. The reason is that people have no habits and no equipment to test frequently. Our POCT software reduces the difficulty of in vitro diagnosis, prompts people to get used to in vitro diagnosis in life, and turns high-cost low-frequency detection into low-cost high-frequency detection.”
LINZHI Technology’s POCT algorithm was developed in September 2018. The company is currently preparing for CFDA and FDA certification. In the future, it may face three major application scenarios: early detection of tumors, food hygiene and safety testing, and disease detection of pets.
Huang Jie said: “LINZHI Technology can determine whether there is a tumor in the user’s body by detecting the user’s tumor markers. If the user’s test results show that the tumor markers are high, the patient may have cancer. Our test results are not given The patient diagnosed the cancer, but told the patient that he may have a cancer risk through the tumor marker, allowing the patient to be screened, prevented, and treated in advance.”
Regarding the future, the company is mainly aimed at C-end users. Its goal is to become a grassroots early screening service provider. With lower detection cost and better user experience, the low-frequency to high-frequency will be transformed, and the serious illness will be killed. in. In the case of B-side customers, the company focuses on drug and drug abuse testing, providing technical services and support to national functional agencies and departments. Huang Jieyu said that LINZHI Technology will continue to explore the future direction.
At present, LINZHI Technology has launched Angel Wheel financing, and plans to raise RMB 5 million for qualification certification, product development and R&D, intellectual property protection, and product testing.